Roche says Phase II trial shows enicepatide cuts HbA1c 2.65% in type 2 diabetes patients at 48 weeks
Late-stage development plans
Roche is running two Phase III weight-management studies, with Phase III diabetes and cardiovascular outcomes programs planned for 1H 2027.
Weight loss and safety findings
Participants also recorded sustained weight loss over the study period, supporting enicepatide’s positioning in cardiometabolic disease.
Safety broadly matched the incretin class, with mostly mild-to-moderate gastrointestinal effects and low treatment discontinuations.
Phase II results in type 2 diabetes
Roche reported positive topline Phase II results for enicepatide, a once-weekly dual GLP-1/GIP agonist, in type 2 diabetes.
The trial showed clinically meaningful improvements in blood sugar control, with many patients reaching diabetes targets or normal-range glucose levels.
